Pyridazines

Abstract

The present invention relates to novel pyridazines, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment and/or prevention of diseases and disorders mediated by Autotaxin.

1 . A compound according to formula (I) 
       
         
           
           
               
               
           
         
         wherein 
         A is pyridyl substituted with one or two members of the group consisting of fluoro and F 1-7 -fluoro-C 1-3 -alkyl; 
         E is selected from the group consisting of phenyl and pyridyl optionally substituted with one or two members of the group consisting of fluoro and F 1-7 -fluoro-C 1-3 -alkyl; 
         K is selected from the group consisting of 
       
       
         
           
           
               
               
           
         
         R 3  is selected from the group consisting of R 4 (O)C—, oxetanyl, methyl, 
         R 5 (O)C(CH 3 )N— and R 5 (O)CHN—;
 R 4  is methyl; 
 R 5  is methyl. 
 
       
     
     
         2 . The compound of formula (I) according to  claim 1 , wherein A is pyridyl substituted with one or two members of the group consisting of F and F 1-3 -fluoro-C 1 -alkyl. 
     
     
         3 . The compound of formula (I) according to  claim 1 , wherein A is selected from the group consisting of 
       
         
           
           
               
               
           
         
       
     
     
         4 . The compound of formula (I) according to  claim 1 , wherein E is selected from the group consisting of phenyl and pyridyl optionally substituted with one or two members of the group consisting of F, F 2 HC, and F 3 C. 
     
     
         5 . The compound of formula (I) according to  claim 1 , wherein E is selected from the group consisting of 
       
         
           
           
               
               
           
         
       
     
     
         6 . The compound of formula (I) according to  claim 1 , selected from the group consisting of 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
     
     
         7 . A pharmaceutical composition comprising at least one compound of formula (I) according to  claim 1  or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients. 
     
     
         8 . A method for the treatment or prevention of inflammatory airway diseases or fibrotic diseases comprising administering to a patient a compound of formula (I) according to  claim 1  or pharmaceutically acceptable salt thereof. 
     
     
         9 . The method according to  claim 8 , wherein said method is for the treatment or prevention of idiopathic lung disease (IPF) or systemic sclerosis (SSc).